High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.

@article{AlKadhimi2014HighIO,
  title={High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.},
  author={Zaid S. Al-Kadhimi and Zartash Gul and Wei Chen and Daryn W. Smith and Muneer H. Abidi and Abhinav Deol and Lois J. Ayash and Lawrence G. Lum and Edmund K Waller and Voravit Ratanatharathorn and Joseph P. Uberti},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2014},
  volume={20 7},
  pages={
          979-85
        }
}
Both acute and chronic graft-versus-host disease (GVHD) are major causes of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). The optimal pharmacological regimen for GVHD prophylaxis is unclear, but combinations of a calcineurin inhibitor (cyclosporin or tacrolimus [Tac]) and an antimetabolite (methotrexate or mycophenolate mofetil [MMF]) are typically used. We retrospectively evaluated the clinical outcomes of 414 consecutive patients… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis.

  • Betty Hamilton, Matt E. Kalaycio
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2014
VIEW 7 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.

VIEW 2 EXCERPTS
CITES RESULTS & BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES

Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation.

VIEW 13 EXCERPTS
HIGHLY INFLUENTIAL

Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.

VIEW 3 EXCERPTS

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.

VIEW 1 EXCERPT

HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.

VIEW 1 EXCERPT